Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

XML

Research Article

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Online download statistics by month:

Online download statistics by month: January 2020 to April 2023

	Abstract	Full	Pdf
Jan 2020	5	5	0
Feb 2020	42	42	0
Mar 2020	38	38	2
Apr 2020	25	25	20
May 2020	33	33	19
Jun 2020	31	31	48
Jul 2020	29	29	12
Aug 2020	74	73	25
Sep 2020	68	68	25
Oct 2020	45	45	25
Nov 2020	57	57	24
Dec 2020	32	30	28
Jan 2021	51	51	32
Feb 2021	50	50	35
Mar 2021	63	63	31
Apr 2021	75	75	37
May 2021	104	104	77
Jun 2021	76	76	30
Jul 2021	93	93	47
Aug 2021	85	85	40
Sep 2021	87	87	33
Oct 2021	74	74	60
Nov 2021	50	50	47
Dec 2021	55	57	36
Jan 2022	58	70	33
Feb 2022	68	76	53
Mar 2022	53	53	26
Apr 2022	55	58	28
May 2022	35	37	27
Jun 2022	52	53	23
Jul 2022	46	48	17
Aug 2022	55	56	21
Sep 2022	61	64	28
Oct 2022	57	59	22
Nov 2022	39	45	39
Dec 2022	42	43	25
Jan 2023	59	63	22
Feb 2023	53	54	19
Mar 2023	67	67	28
Apr 2023	35	36	25
Total	2177	2223	1169